Belite Bio, Inc. has received FDA acceptance for its new drug application (NDA) for tinlarebant, an interventional therapy for the treatment of Stargardt disease type 1 (STGD1).
And let’s not forget: This news follows less than 2 months after the company completed rolling submission of its application.
I could’ve sworn we just heard from Belite …
You’re not wrong. In fact we just (as in last week) reported on the company’s recent presentation of updated phase 3 data for this investigational candidate.
But more on that later.
Well then, let’s get a refresher on this therapeutic.
The once-daily, orally-administered tablet is formulated to intervene early and maintain retinal tissue health among patients with STGD1.
Its mechanism of action: involves reducing toxic accumulation within the eye that leads to STGD1 development. Click here for a more detailed breakdown and description of the process.
Now circle back to its clinical data—how has it performed?
For these details, we’ll refer to the topline data from the phase 3 global DRAGON trial included in tinlarebant’s NDA submission.
A brief look at those findings: The study met its primary endpoint, demonstrating “a statistically significant and clinically meaningful" 36% reduction in retinal lesion growth versus placebo.
- Click here for the full data readout, as we covered in December 2025.
And more recently?
That updated phase 3 data mentioned earlier was also from the DRAGON study, in which investigators shared positive secondary endpoint data.
That data readout: Found tinlarebant decreased retinol binding protein 4 (RBP4) levels by 80%, and met its primary goal of a statistically significant 35.7% slowing of definitively decreased autofluorescence (DDAF) lesion growth—as compared to placebo at 25 months.
But also take note: These most recent results were not included in tinalarebant’s NDA submission.
Duly noted. And you mentioned this NDA was submitted on a rolling basis?
That we did—check out what this process entails.
Notably: This staggered submission was thanks in part to two (of the four) FDA designations granted to tinlarebant for its STGD1 indication: Fast Track and Breakthrough Therapy (BTD) designations.
Also important: The NDA was submitted under its BTD, which also made Belite eligible to receive priority review for the SGTD1 therapeutic—not to mention more frequent interactions with the FDA.
… so was this priority review granted?
Indeed it was.
What this means: The review period for tinlarebant’s NDA leading up to the Prescription Drug User Fee Act (PDUFA) will only be 6 months (instead of the standard 10-month duration).
… which brings us to when?
The FDA has set the PDUFA target action date for Feb. 12, 2027.
And the big-picture significance?
Pending this FDA approval: Tinlarebant could become the first-ever treatment for STGD1.